- $20.73m
- $17.23m
- $8.27m
- 45
- 59
- 82
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 23.6 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1268.43% | ||
| Return on Equity | -2101.98% | ||
| Operating Margin | -149.81% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.44 | 17.12 | 9.89 | 10.25 | 8.27 | 9.3 | n/a | 16.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +1465.64 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TRxADE Health, Inc. provides a technology-enabled health services platform. The Company is focused on digitalizing the retail pharmacy and health services experience by optimizing drug procurement, the prescription journey, access to physicians in the patient’s home and patient engagement in the United States. The Company’s segments include Trxade, Inc., Integra Pharma Solutions, LLC (IPS) and Superlatus. Trxade, Inc. segment provides a web-based pharmaceutical marketplace platform-business to business (B2B) sales. IPS is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. The Superlatus segment holds Sapientia’s intellectual property for advanced food extrusion technology and The Urgent Company, which is a manufacturer of ice cream that is animal product-free, vegan, lactose-free, and made with plant-B2B sales. Its subsidiaries include Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC, Bonum Health, LLC and others.
Directors
- Surendra Ajjarapu CHM (50)
- Prashant Patel PRE (46)
- Howard Doss CFO (67)
- Donald Fell IND (74)
- Christine Jennings IND (75)
- Charles Pope IND (70)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 15th, 2005
- Public Since
- February 18th, 2020
- No. of Shareholders
- 52
- No. of Employees
- 8
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,406,348
- Address
- 2420 Brunello Trace, LUTZ, 33558
- Web
- https://www.trxadehealth.com/
- Phone
- +1 8136013533
- Auditors
- Malone Bailey, LLP
Upcoming Events for MEDS
Similar to MEDS
Abits
NASDAQ Capital Market
Ads-Tec Energy
NASDAQ Capital Market
AdTheorent Holding
NASDAQ Capital Market
Advanced Health Intelligence
NASDAQ Capital Market
AGM group
NASDAQ Capital Market
FAQ
What is the Trxade Health share price?
As of Today at 23:50 UTC, shares in Trxade Health are trading at $9.10. This share price information is delayed by 15 minutes.
How has the Trxade Health share price performed this year?
Shares in Trxade Health last closed at $9.10 and the price had moved by +86.71% over the past 365 days. In terms of relative price strength the Trxade Health share price has outperformed the S&P500 Index by +48.57% over the past year.
What are the analyst and broker recommendations for Trxade Health?
The overall consensus recommendation for Trxade Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Trxade Health dividend yield?
Trxade Health does not currently pay a dividend.
Does Trxade Health pay a dividend?
Trxade Health does not currently pay a dividend.
When does Trxade Health next pay dividends?
Trxade Health does not currently pay a dividend.
How do I buy Trxade Health shares?
To buy shares in Trxade Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Trxade Health?
As of the previous close price of $9.10, shares in Trxade Health had a market capitalisation of $12.80m.
Where are Trxade Health shares listed?
Here are the trading details for Trxade Health:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MEDS
What kind of share is Trxade Health?
Based on an overall assessment of its quality, value and momentum Trxade Health is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Trxade Health share price forecast for 2024?
The analyst consensus target price for shares in Trxade Health is $6.75. That is 25.82% below the last closing price of $9.10.
Analysts covering Trxade Health currently have a consensus Earnings Per Share (EPS) forecast of -$0.45 for the next financial year.
What is the trend in the Trxade Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Trxade Health. Over the past six months, its share price has outperformed the S&P500 Index by +140.93%.
As of the last closing price of $9.10, shares in Trxade Health were trading +54.89% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Trxade Health PE Ratio?
The Trxade Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Trxade Health?
Trxade Health's management team is headed by:
- Surendra Ajjarapu - CHM
- Prashant Patel - PRE
- Howard Doss - CFO
- Donald Fell - IND
- Christine Jennings - IND
- Charles Pope - IND